Phase II Study of Minocycline for Reducing Symptom Burden in Colorectal Patients
Phase 2
Completed
- Conditions
- Colorectal Cancer
- Interventions
- First Posted Date
- 2013-07-23
- Last Posted Date
- 2020-03-17
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 122
- Registration Number
- NCT01906008
- Locations
- 🇺🇸
LBJ Hospital, Houston, Texas, United States
🇺🇸University of Texas MD Anderson Cancer Center, Houston, Texas, United States
STAT3 Inhibitor WP1066 in Treating Patients With Recurrent Malignant Glioma or Progressive Metastatic Melanoma in the Brain
Phase 1
Completed
- Conditions
- Metastatic Malignant Neoplasm in the BrainMetastatic MelanomaRecurrent Brain NeoplasmRecurrent GlioblastomaRecurrent Malignant Glioma
- Interventions
- First Posted Date
- 2013-07-22
- Last Posted Date
- 2022-03-23
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 8
- Registration Number
- NCT01904123
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Natural Killer Cells Before and After Donor Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia
Phase 1
Completed
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 PositiveMyelodysplastic SyndromeAcute Myeloid Leukemia Arising From Previous Myelodysplastic SyndromeAcute Myeloid Leukemia With Gene MutationsRecurrent Chronic Myelogenous Leukemia, BCR-ABL1 PositiveBlast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positivede Novo Myelodysplastic SyndromeRecurrent Acute Myeloid LeukemiaTherapy-Related Acute Myeloid Leukemia
- Interventions
- Procedure: Allogeneic Hematopoietic Stem Cell TransplantationProcedure: Bone Marrow TransplantationOther: Laboratory Biomarker AnalysisBiological: Natural Killer Cell TherapyProcedure: Peripheral Blood Stem Cell TransplantationRadiation: Total-Body Irradiation
- First Posted Date
- 2013-07-22
- Last Posted Date
- 2024-01-24
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 54
- Registration Number
- NCT01904136
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Feasibility - Beta Adrenergic Blockade (BB) in Cervical Cancer (CX)
Not Applicable
Terminated
- Conditions
- Cervical Cancer
- Interventions
- First Posted Date
- 2013-07-18
- Last Posted Date
- 2021-10-12
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 6
- Registration Number
- NCT01902966
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸Lyndon B. Johnson General Hospital (LBJ), Houston, Texas, United States
Sorafenib Tosylate and Yttrium Y 90 Glass Microspheres in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery
Phase 2
Completed
- Conditions
- Advanced Adult Hepatocellular CarcinomaStage IIIA Hepatocellular Carcinoma AJCC v7Stage IVB Hepatocellular Carcinoma AJCC v7Stage IIIC Hepatocellular Carcinoma AJCC v7Stage IV Hepatocellular Carcinoma AJCC v7Stage IVA Hepatocellular Carcinoma AJCC v7BCLC Stage C Hepatocellular CarcinomaRecurrent Adult Hepatocellular CarcinomaStage III Hepatocellular Carcinoma AJCC v7Stage IIIB Hepatocellular Carcinoma AJCC v7
- Interventions
- Other: Laboratory Biomarker AnalysisOther: Quality-of-Life AssessmentRadiation: Yttrium Y 90 Glass Microspheres
- First Posted Date
- 2013-07-16
- Last Posted Date
- 2021-12-30
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 40
- Registration Number
- NCT01900002
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Study of Valproic Acid (VPA) vs Placebo to Shorten Time of Indwelling Pleural Catheter
Phase 2
Terminated
- Conditions
- Breast Cancer
- Interventions
- Drug: PlaceboDrug: Valproic Acid (VPA)Behavioral: QuestionnairesBehavioral: Pill DiaryBehavioral: Drainage Diary
- First Posted Date
- 2013-07-16
- Last Posted Date
- 2020-02-25
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 3
- Registration Number
- NCT01900730
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Ferumoxytol - Iron Oxide Nanoparticle Magnetic Resonance Dynamic Contrast Enhanced MRI
Early Phase 1
Terminated
- Conditions
- Head and Neck Cancer
- Interventions
- Procedure: Magnetic Resonance Imaging (MRI)
- First Posted Date
- 2013-07-11
- Last Posted Date
- 2021-09-21
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 7
- Registration Number
- NCT01895829
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Ruxolitinib for Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
- First Posted Date
- 2013-07-11
- Last Posted Date
- 2025-02-28
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 31
- Registration Number
- NCT01895842
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Contrast Enhanced Intraoperative Ultrasound for Detection and Characterization of Renal Mass Undergoing Open Partial Nephrectomy
Not Applicable
Completed
- Conditions
- Kidney Cancer
- Interventions
- First Posted Date
- 2013-07-10
- Last Posted Date
- 2016-04-14
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 11
- Registration Number
- NCT01894607
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Eltrombopag With or Without Hypomethylating Agent After Hypomethylating Agent Failure For Patients With Myelodysplastic Syndrome (MDS)
- First Posted Date
- 2013-07-09
- Last Posted Date
- 2020-02-18
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 29
- Registration Number
- NCT01893372
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States